Lung cancer: immunotherapy of drug and radio resistant breast cancer

Diseases: Lung cancer and all other malignant neoplasms resistant to the chemotherapy, patients with relative and absolute contraindications to surgical interventions, chemotherapy and radiation therapy (implanted pacemakers, artificial organs, severe forms of absolute arrhythmia, circulatory deficiency of 3 stage, severe forms of diabetes mellites etc.)

Therapy principle: The malignant tumor is heterogeneous and consists of the tumor cells and the cells of microenvironment (macrophages, dendritic cells, lymphocytes), which make up to 80% of the size of the neoplasm. Normal microenvironment cells provide protection for the tumor cells from external factors, including chemotherapy. They also mask antigens on the surface of malignant cells, reducing the effectiveness of immunotherapy. The administration of patient’s own cytotoxic lymphocytes that have been expanded with antigen-presenting cells loaded with tumor antigens allows to affect not only malignant cells, but also microenvironment cells inducing their apoptosis (program death). Having lost the support and protective microenvironment, the resistant tumor often becomes sensitive even to that chemotherapy to which it has been resistant before. The cell products are prepared for 2 to 3 weeks, which must be taken into account when planning this therapy for resistant, progressing cases.

Result: Survival rates of drug resistant cancer patients increase by 1.5 to 2 times; opportunity to receive effective alternative therapy in the cases with counterindications to the surgery, chemo- and radiotherapy.